Denileukin Diftitox (Ontak)

Phase 1Terminated
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Myeloma

Conditions

Multiple Myeloma

Trial Timeline

Nov 1, 2010 โ†’ May 1, 2013

About Denileukin Diftitox (Ontak)

Denileukin Diftitox (Ontak) is a phase 1 stage product being developed by Eisai for Multiple Myeloma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01251952. Target conditions include Multiple Myeloma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT01432483Pre-clinicalCompleted
NCT01251952Phase 1Terminated

Competing Products

20 competing products in Multiple Myeloma

See all competitors